Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA

Key Points

• Dimensional Fund Advisors increased its Protara Therapeutics stake by 133.9% in the first quarter, reaching 531,267 shares valued at approximately $2.77 million. Hedge funds and other institutional investors collectively own 38.13% of TARA.
• Protara shares opened at $3.94, near the lower end of their 52-week range of $2.97 to $7.82. The company reported a quarterly loss of $0.36 per share, missing analyst expectations by $0.03.
• Analysts maintain a generally positive outlook, with seven Buy ratings and one Sell rating. Protara has a consensus “Moderate Buy” rating and an average price target of $26.25.

Dimensional Fund Advisors LP boosted its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 133.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 531,267 shares of the company's stock after buying an additional 304,110 shares during the quarter. Dimensional Fund Advisors LP owned 0.96% of Protara Therapeutics worth $2,767,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in TARA. Bank of New York Mellon Corp boosted its stake in shares of Protara Therapeutics by 38.7% during the 1st quarter. Bank of New York Mellon Corp now owns 129,671 shares of the company's stock worth $676,000 after acquiring an additional 36,149 shares in the last quarter. AIGH Capital Management LLC purchased a new position in Protara Therapeutics in the 1st quarter valued at approximately $8,454,000. Assenagon Asset Management S.A. increased its stake in Protara Therapeutics by 84.1% in the 1st quarter. Assenagon Asset Management S.A. now owns 567,621 shares of the company's stock valued at $2,957,000 after purchasing an additional 259,287 shares in the last quarter. Virtu Financial LLC acquired a new position in Protara Therapeutics during the fourth quarter worth $368,000. Finally, ADAR1 Capital Management LLC raised its holdings in Protara Therapeutics by 3,127.4% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company's stock worth $6,059,000 after purchasing an additional 1,101,576 shares during the last quarter. 38.13% of the stock is owned by hedge funds and other institutional investors.

Protara Therapeutics Stock Performance

Shares of TARA opened at $3.94 on Friday. The stock has a fifty day moving average of $4.03 and a two-hundred day moving average of $5.03. The company has a market capitalization of $232.85 million, a PE ratio of -2.92 and a beta of 1.50. Protara Therapeutics, Inc. has a fifty-two week low of $2.97 and a fifty-two week high of $7.82.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.03). As a group, equities research analysts forecast that Protara Therapeutics, Inc. will post -1.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TARA has been the subject of a number of research analyst reports. Wall Street Zen upgraded Protara Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, May 16th. JPMorgan Chase & Co. decreased their price objective on shares of Protara Therapeutics from $27.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, May 14th. UBS Group reiterated a "buy" rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Oppenheimer increased their price objective on shares of Protara Therapeutics from $25.00 to $28.00 and gave the company an "outperform" rating in a research note on Wednesday, May 20th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Protara Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $26.25.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company's primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body's immune response to target tumor cells. Protara's therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara's lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source